Search results
Results from the WOW.Com Content Network
Insulin glargine sold under the brand name Lantus among others is a long-acting modified form of medical insulin, used in the management of type 1 and type 2 diabetes. [7] It is injected just under the skin. [7] Effects generally begin an hour after use. [7]
It works the same as human insulin by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver. [5] Insulin lispro was first approved for use in the United States in 1996. [5] [8] [9] It is a manufactured analogue of human insulin where two amino acids have swapped positions. [10]
This is an ultralong-acting insulin analogue developed by Novo Nordisk, which markets it under the brand name Tresiba. It is administered once daily and has a duration of action that lasts up to 40 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir).
Umeclidinium bromide is a long-acting muscarinic antagonist. [14] This combination was approved by the FDA on December 18, 2013 [15] for the long-term maintenance treatment of COPD. On March 28, 2014, it was approved in European countries [16] and in Russia [17] under the same trade name.
Novo Nordisk scientist Lotte Bjerre Knudsen paved the way for popular GLP-1 drugs like Ozempic. Her work in the 1990s was instrumental in turning short-acting hormones into long-acting drugs.
[18] [19] The anti-obesity effects of amphetamines, besides acting on the brain to reduce energy intake, are also mediated by the beta-2 adrenergic receptor. [ 20 ] [ 17 ] Ephedrine (and related compounds that are also active ingredients in ephedra preparations) exert their effects by acting directly and indirectly as adrenergic agonists.
The Food and Drug Administration approved on Thursday the first drug designed to prevent migraines. A once-monthly, self-injection, Aimovig is the first in a new class of long-acting drugs that is ...
New drugs to treat debilitating menopause symptoms — namely hot flashes — are finally on the market or are in development. But doctors say insurance companies either won’t pay for them or ...